TherapeuticsMD
TXMD
131 hedge funds and large institutions have $44.1M invested in TherapeuticsMD in 2021 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 31 increasing their positions, 50 reducing their positions, and 31 closing their positions.
111% more call options, than puts
Call options by funds: $438K | Put options by funds: $208K
2.24% less ownership
Funds ownership: 31.42% → 29.18% (-2.2%)
11% less funds holding
Funds holding: 148 → 131 (-17)
38% less repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 50
54% less capital inflows, than outflows
Capital inflows: $4.68M | Capital outflows: $10.3M
77% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 31
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$730K |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
+$572K |
| 3 |
Nomura Holdings
Tokyo,
Japan
|
+$537K |
| 4 |
D.E. Shaw & Co
New York
|
+$527K |
| 5 |
AMG
Asset Management Group
Stamford,
Connecticut
|
+$429K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Sanders Morris Harris
Houston,
Texas
|
-$1.83M |
| 2 |
Nuveen
Charlotte,
North Carolina
|
-$1.13M |
| 3 |
Brandywine Global Investment Management
Philadelphia,
Pennsylvania
|
-$755K |
| 4 |
Swiss National Bank
Zurich,
Switzerland
|
-$621K |
| 5 |
Millennium Management
New York
|
-$494K |
TXMD Hedge Fund Activity: Q4 2021 in Review
131 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in TherapeuticsMD (TXMD) for Q4 2021, worth a combined $44.1M — down 55% from $98.2M a quarter earlier.
Sellers outnumbered buyers: 31 funds closed out of TXMD and 7 opened new positions — a net loss of 24 holders — while 50 trimmed existing stakes and 31 added.
The largest buyer was Vanguard Group, adding an estimated $730K. The largest seller was Sanders Morris Harris, cutting an estimated $1.83M.
- 131 institutional investors held TherapeuticsMD (TXMD) as of Q4 2021, down from 148 in Q3 2021.
- Funds reported $44.1M of TherapeuticsMD stock for Q4 2021, down 55% quarter-over-quarter.
- 7 funds opened new TherapeuticsMD positions in Q4 2021 and 31 closed out, a net change of -24 holders.
- The largest TherapeuticsMD buyer in Q4 2021 was Vanguard Group, an estimated $730K added.
- The largest TherapeuticsMD seller in Q4 2021 was Sanders Morris Harris, an estimated $1.83M sold.
Based on aggregated 13F filings for Q4 2021.